Generalized pustular psoriasis (shortened to GPP) is a rare, potentially life-threatening disease in which pus-filled blisters or pustules may suddenly form all over the body. The drug spesolimab has been approved to treat worsening GPP (known as flares) in many countries. However, it was not known if spesolimab could prevent the symptoms of GPP. This summary reports the results from a clinical study called Effisayil™ 2, that was done to understand if spesolimab was a safe and effective way to prevent flares in people with GPP. In the study, 123 participants, recruited in 20 different countries, were given one of three different doses of spesolimab (low, medium, or high) or a non-active medicine (placebo) over 48 weeks.This Plain Language Summary of Publication article (PLSP) from Future Rare Diseases focuses on a rare, potentially life-threatening, disease called Generalized pustular psoriasis (shortened to GPP). People with the disease will have pus-filled blisters form all over the body. The Effisayil™ 2 study looked at whether an approved drug, known as spesolimab, could prevent the symptoms of GPP.

Visit the Future Medicine using the link to read the article.

This PLSP is based on an original article called ‘Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial’ and was published in The Lancet.

Visit The Lancet using the link to read the article.